Clinical study of an LH-RH agonist (ICI 118.630, Zoladex) in the treatment of prostatic cancer.
Eighty patients with prostatic cancer have been treated with an LH-RH analogue (Zoladex). Ten had no metastasis, and hormone therapy was used as an induction treatment before curative radiotherapy. The others had metastatic disease and, in some cases, had already received some form of endocrine therapy. Patients received a monthly injection of Zoladex (3.6 mg). No progressive disease was noted among patients with nonmetastatic tumors; of the patients with metastases, those who were previously untreated had a higher response rate (14.8% complete response) and longer progression-free and overall survival. Toxicity was mild in spite of two cases of disease flare.
Mauriac
L
L
Department of Clinical Oncology, Fondation Bergonie, Bordeaux, France.
Coste
P
P
Richaud
P
P
Lamarche
P
P
Mage
P
P
Bonichon
F
F
D000368:Aged; D000369:Aged, 80 and over; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D002064:Buserelin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy*; D003692:Delayed-Action Preparations; D017273:Goserelin; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012074:Remission Induction
D003692:Delayed-Action Preparations; D017273:Goserelin; D002064:Buserelin